Skip to main content

Advertisement

SpringerLink
Log in

Clinically relevant biomarkers in targeted radiotherapy

  • Research Paper
  • Published:
Clinical & Experimental Metastasis Aims and scope Submit manuscript

Abstract

Three classic parameters have been recognized as predictors or biomarkers of radiation response: intrinsic radiosensitivity, degree of hypoxia and repopulation capacity of clonogenic cells during a course of fractionated radiation therapy. Although good functional assays exist to measure these tumor parameters, and their use has led to the understanding of factors affecting outcome after radiotherapy, their application in clinical practice is hampered by technical difficulties, the length of time needed to obtain results and the lack of prospective randomized clinical trials. Recently, with the progress in molecular biology, genome-wide screening methods have been used to look for genetic signatures that can distinguish between good and bad outcome after radiotherapy. One of the most promising candidates is the epidermal growth factor receptor which is overexpressed or mutated in a variety of malignancies, such lung and head and neck cancer. Inhibition of this receptor has led to radio-sensitization with the prolongation of median survival in several cancers. Since there is significant variability in the response of patients with the same disease to radiotherapy, it would be very valuable to be able to predict which patients would benefit from a molecularly targeted therapy administered with concomitant radiation in order to increase the response rate (and cure rate) of those patients with radioresistant tumors. Optimally, this assay should be able to provide results in an efficient and reproducible manner and detect tumor genetic mutations that would provide specificity to the intervention. One approach currently in clinical practice to overcome intrinsic radioresistance and repopulation is stereotactic body radiotherapy coupled with image-guided radiation, a highly precise and powerful form of radiation, allowing radiation oncologist to treat tumors with more aggressive biological doses of radiation without causing serious normal tissues injury.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Williams FH (1901) The Roentgen rays in medicine and surgery as an aid in diagnosis and as a therapeutic agent. The McMillan Company, London

    Google Scholar 

  2. Hall E, Giaccia A (2006) Radiobiology for the radiologist, 6th edn. JB Lippincott, Philadelphia

    Google Scholar 

  3. Overgaard J, Hansen HS, Andersen AP, Hjelm-Hansen M, Jørgensen K, Sandberg E, Berthelsen A, Hammer R, Pedersen M (1989) Misonidazole combined with split-course radiotherapy in the treatment of invasive carcinoma of larynx and pharynx: report from the DAHANCA 2 study. Int J Radiat Oncol Biol Phys 16(4):1065–1068

    Article  PubMed  CAS  Google Scholar 

  4. Hoff CM, Grau C, Overgaard J (2012) Effect of smoking on oxygen delivery and outcome in patients treated with radiotherapy for head and neck squamous cell carcinoma—a prospective study. Radiother Oncol 103(1):38–44

    Article  PubMed  Google Scholar 

  5. Hockel M, Schlenger K, Aral B, Mitze M, Schaffer U, Vaupel P (1996) Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. Cancer Res 56(19):4509–4515

    PubMed  CAS  Google Scholar 

  6. Brizel DM, Dodge RK, Clough RW, Dewhirst MW (1999) Oxygenation of head and neck cancer: changes during radiotherapy and impact on treatment outcome. Radiother Oncol 53(2):113–117

    Article  PubMed  CAS  Google Scholar 

  7. Bennett M, Feldmeier J, Smee R, Milross C (2007) Hyperbaric oxygenation for tumour sensitisation to radiotherapy: a systematic review of randomised controlled trials. Cancer Treat Rev 34(7):577–591

    Article  Google Scholar 

  8. Marotta D, Karar J, Jenkins WT, Kumanova M, Jenkins KW, Tobias JW, Baldwin D, Hatzigeorgiou A, Alexiou P, Evans SM, Alarcon R, Maity A, Koch C, Koumenis C (2011) In vivo profiling of hypoxic gene expression in gliomas using the hypoxia marker EF5 and laser-capture microdissection. Cancer Res 71(3):779–789

    Article  PubMed  CAS  Google Scholar 

  9. Seigneuric R, Starmans MH, Fung G, Krishnapuram B, Nuyten DS, van Erk A, Magagnin MG, Rouschop KM, Krishnan S, Rao RB, Evelo CT, Begg AC, Wouters BG, Lambin P (2007) Impact of supervised gene signatures of early hypoxia on patient survival. Radiother Oncol 83(3):374–382

    Article  PubMed  CAS  Google Scholar 

  10. Bristow RG, Hill RP (2008) Hypoxia and metabolism. Hypoxia, DNA repair and genetic instability. Nat Rev Cancer 8(3):180–192

    Article  PubMed  CAS  Google Scholar 

  11. Overgaard J, Hjelm-Hansen M, Johansen LV, Andersen AP (1988) Comparison of conventional and split-course radiotherapy as primary treatment in carcinoma of the larynx. Acta Oncol 27(2):147–152

    Article  PubMed  CAS  Google Scholar 

  12. Overgaard J, Hansen HS, Specht L, Overgaard M, Grau C, Andersen E, Bentzen J, Bastholt L, Hansen O, Johansen J, Andersen L, Evensen JF (2003) Five compared with six fractions per week of conventional radiotherapy of squamous-cell carcinoma of head and neck: DAHANCA 6 and 7 randomised controlled trial. Lancet 362(9388):933–940

    Article  PubMed  Google Scholar 

  13. Fu KK, Pajak TF, Trotti A, Jones CU, Spencer SA, Phillips TL, Garden AS, Ridge JA, Cooper JS, Ang KK (2000) A Radiation Therapy Oncology Group (RTOG) phase III randomized study to compare hyperfractionation and two variants of accelerated fractionation to standard fractionation radiotherapy for head and neck squamous cell carcinomas: first report of RTOG 9003. Int J Radiat Oncol Biol Phys 48(1):7–16

    Article  PubMed  CAS  Google Scholar 

  14. Withers HR, Maciejewski B, Taylor JM, Hliniak A (1988) Accelerated repopulation in head and neck cancer. Front Radiat Ther Oncol 22:105–110

    PubMed  CAS  Google Scholar 

  15. Fyles A, Keane TJ, Barton M, Simm J (1992) The effect of treatment duration in the local control of cervix cancer. Radiother Oncol 4:273–279

    Article  Google Scholar 

  16. Starmans MH, Krishnapuram B, Steck H, Horlings H, Nuyten DS, van de Vijver MJ, Seigneuric R, Buffa FM, Harris AL, Wouters BG, Lambin P (2008) Robust prognostic value of a knowledge-based proliferation signature across large patient microarray studies spanning different cancer types. Br J Cancer 99(11):1884–1890

    Article  PubMed  CAS  Google Scholar 

  17. West CM, Davidson SE, Roberts SA, Hunter RD (1997) The independence of intrinsic radiosensitivity as a prognostic factor for patient response to radiotherapy of carcinoma of the cervix. Br J Cancer 76(9):1184–1190

    Article  PubMed  CAS  Google Scholar 

  18. Björk-Eriksson T, West CM, Karlsson E, Slevin NJ, Davidson SE, James RD, Mercke C (1998) The in vitro radiosensitivity of human head and neck cancers. Br J Cancer 77(12):2371–2375

    Article  PubMed  Google Scholar 

  19. Björk-Eriksson T, West C, Karlsson E, Mercke C (2000) Tumor radiosensitivity (SF2) is a prognostic factor for local control in head and neck cancers. Int J Radiat Oncol Biol Phys 46(1):13–19

    Article  PubMed  Google Scholar 

  20. Olive PL (2011) Retention of γH2AX foci as an indication of lethal DNA damage. Radiother Oncol 101(1):18–23

    Article  PubMed  CAS  Google Scholar 

  21. Buyyounouski MK, Balter P, Lewis B, D’Ambrosio DJ, Dilling TJ, Miller RC, Schefter T, Tomé W, Harris EE, Price RA Jr, Konski AA, Wallner PE (2012) Stereotactic body radiotherapy for early-stage non-small-cell lung cancer: report of the ASTRO emerging technology committee. Int J Radiat Oncol Biol Phys 78(1):3–10

    Article  Google Scholar 

  22. Bral S, Gevaert T, Linthout N, Versmessen H, Collen C, Engels B, Verdries D, Everaert H, Christian N, De Ridder M, Storme G (2011) Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a phase II trial. Int J Radiat Oncol Biol Phys 80(5):1343–1349

    Article  PubMed  Google Scholar 

  23. Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, Fakiris A, Bezjak A, Videtic G, Johnstone D, Fowler J, Gore E, Choy H (2010) Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA 303(11):1070–1076

    Article  PubMed  CAS  Google Scholar 

  24. Gupta AK, McKenna WG, Weber CN, Feldman MD, Goldsmith JD, Mick R, Machtay M, Rosenthal DI, Bakanauskas VJ, Cerniglia GJ, Bernhard EJ, Weber RS, Muschel RJ (2002) Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. Clin Cancer Res 8(3):885–892

    PubMed  Google Scholar 

  25. Ang KK, Berkey BA, Tu X, Zhang HZ, Katz R, Hammond EH, Fu KK, Milas L (2002) Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res 62(24):7350–7356

    PubMed  CAS  Google Scholar 

  26. Vincent MD, Kuruvilla MS, Leighl NB, Kamel-Reid S (2012) Biomarkers that currently affect clinical practice: EGFR. ALK, MET, KRAS Curr Oncol 19(1):S33–S44

    CAS  Google Scholar 

  27. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, Ove R, Kies MS, Baselga J, Youssoufian H, Amellal N, Rowinsky EK, Ang KK (2006) Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 354(6):567–578

    Article  PubMed  CAS  Google Scholar 

  28. Curran D, Giralt J, Harari PM, Ang KK, Cohen RB, Kies MS, Jassem J, Baselga J, Rowinsky EK, Amellal N, Comte S, Bonner JA (2007) Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. J Clin Oncol 25(16):2191–2197

    Article  PubMed  CAS  Google Scholar 

  29. Chinnaiyan P, Huang S, Vallabhaneni G, Armstrong E, Varambally S, Tomlins SA, Chinnaiyan AM, Harari PM (2005) Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva). Cancer Res 65(8):3328–3335

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Radiation Oncology, University of Arizona, Tucson, AZ, 85724, USA

    Baldassarre Stea & John Gordon

Authors
  1. Baldassarre Stea
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. John Gordon
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Baldassarre Stea.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stea, B., Gordon, J. Clinically relevant biomarkers in targeted radiotherapy. Clin Exp Metastasis 29, 853–860 (2012). https://doi.org/10.1007/s10585-012-9523-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10585-012-9523-z

Keywords

Search

Navigation